MedTrace Logo

A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT00364390 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-03-30

No results posted yet for this study

Summary

This is a first in man, Phase I safety study of Anginera in adults with Left Ventricular Dysfunction (LVD) and Reversible Myocardial Ischemia undergoing a CABG procedure.

Conditions

Interventions

DRUG

Anginera, a human tissue replacement therapy

Sponsors & Collaborators

  • Theregen, Inc.

    lead INDUSTRY

Principal Investigators

  • Bartley P Griffith, MD · University of Maryland, Baltimore

  • George Tellides, M.D., Ph.D. · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-11-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00364390 on ClinicalTrials.gov